D-Mannose-6-phosphate (M-6-P) is a terminal monosaccharide of some asparagine-linked (N-linked) oligosaccharides and is also part of an important intermediate in N-linked oligosaccharide biosynthesis. Some lysosomal glycoproteins require M-6-P terminated oligosaccharides for proper targeting and function. Lack of M-6-P or genetic defects in its synthesis or subsequent processing can result in a variety of diseases.
Terri T. Christison, Brian M. De Borba, and Jeffrey S. Rohrer, Dionex Corporation
D-Mannose-6-phosphate (M-6-P) is a terminal monosaccharide of some asparagine-linked (N-linked) oligosaccharides and is also part of an important intermediate in N-linked oligosaccharide biosynthesis. Some lysosomal glycoproteins require M-6-P terminated oligosaccharides for proper targeting and function. Lack of M-6-P or genetic defects in its synthesis or subsequent processing can result in a variety of diseases.
High performance anion exchange chromatography with pulsed amperometric detection (HPAE-PAD) is a well-established technique for determining a large variety of carbohydrates, including M-6-P (1). The HPAE-PAD method described here accurately determines M-6-P added to an acid-hydrolyzed protein.
A Dionex® ICS-3000 Ion Chromatography system with a CarboPac® PA200 (3 × 250 mm) analytical column was used. M-6-P was separated from the components of acid hydrolyzed bovine serum albumin (BSA) with 100 mM sodium hydroxide and 100 mM sodium acetate at 30 °C, a flow rate of 0.5 mL/min, and detected by PAD as described in reference (2).
Figure 1
HPAE-PAD is a selective, sensitive, and accurate method for determining the M-6-P content of a glycoprotein without derivatization (1). Here, we demonstrate an updated HPAE-PAD method for M-6-P determinations using a newer column and improved electrochemical conditions. Because a M-6-P-containing glycoprotein was not commercially available, we hydrolyzed BSA in 6.75 M trifluoroacetic acid (TFA) for 1.5 h at 100 °C (1), and added M-6-P after hydrolysis. Figure 1 shows that M-6-P is well resolved from the components of the hydrolyzed BSA and accurately determined (101 and 104% recoveries). To confirm the M-6-P peak, we treated the two samples with alkaline phosphatase, re-assayed the samples, and assayed the samples for mannose with another HPAE-PAD method (2). The M-6-P peak in each sample disappeared (not shown) and mannose was recovered (96.5 and 96.8%) (Figure 2). Therefore, HPAE-PAD can accurately determine M-6-P in an acid hydrolyzed glycoprotein sample and confirm M-6-P presence by both substrate disappearance and product appearance.
Figure 2
(1) Zhou, Q., Kyazike, J., Edmunds, T., Higgins, E. Anal. Biochem., 2002, 306, 163–170.
(2) Dionex Corporation. Application Note 202, LPN 2076. Sunnyvale, CA, USA, 2008.
Dionex Corporation
1228 Titan Way, P.O. Box 3603, Sunnyvale, CA 94088-3603
tel. (408)737-0700, fax (408)730-9403
Website: www.dionex.com
Automated Sample Preparation (ISO 20122) for MOSH/MOAH in Seasoning Oils
May 6th 2025This work presents an Automated Sample Preparation procedure for MOSH/MOAH analysis of Seasoning Oils. We compare results from a manual epoxidation procedure compliant with DIN 16995 with results based on fully automated sample preparation (epoxidation and saponification) compliant with ISO 20122. In both cases, online clean-up via activated aluminum oxide (AlOx) are used to remove interfering n-alkanes from the MOSH fraction during the HPLC run. Automated data evaluation using a dedicated software (GERSTEL ChroMOH) is presented.
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.